HUE040063T2 - Tumor õssejtek tumorképzõ potenciáljának gátlása BMP-4 segítségével - Google Patents

Tumor õssejtek tumorképzõ potenciáljának gátlása BMP-4 segítségével

Info

Publication number
HUE040063T2
HUE040063T2 HUE06795317A HUE06795317A HUE040063T2 HU E040063 T2 HUE040063 T2 HU E040063T2 HU E06795317 A HUE06795317 A HU E06795317A HU E06795317 A HUE06795317 A HU E06795317A HU E040063 T2 HUE040063 T2 HU E040063T2
Authority
HU
Hungary
Prior art keywords
bmp
inhibition
stem cells
tumor stem
tumorigenic potential
Prior art date
Application number
HUE06795317A
Other languages
English (en)
Inventor
Angelo Luigi Vescovi
Brent Allan Reynolds
Original Assignee
Stemgen S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stemgen S P A filed Critical Stemgen S P A
Publication of HUE040063T2 publication Critical patent/HUE040063T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HUE06795317A 2005-07-19 2006-07-19 Tumor õssejtek tumorképzõ potenciáljának gátlása BMP-4 segítségével HUE040063T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70085905P 2005-07-19 2005-07-19

Publications (1)

Publication Number Publication Date
HUE040063T2 true HUE040063T2 (hu) 2019-02-28

Family

ID=37420973

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE06795317A HUE040063T2 (hu) 2005-07-19 2006-07-19 Tumor õssejtek tumorképzõ potenciáljának gátlása BMP-4 segítségével
HUE16171392A HUE042197T2 (hu) 2005-07-19 2006-07-19 Tumor õssejtek tumorképzõ potenciáljának gátlása LIF segítségével

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE16171392A HUE042197T2 (hu) 2005-07-19 2006-07-19 Tumor õssejtek tumorképzõ potenciáljának gátlása LIF segítségével

Country Status (13)

Country Link
US (2) US9220756B2 (hu)
EP (2) EP3117833B1 (hu)
JP (3) JP5189977B2 (hu)
KR (2) KR101311061B1 (hu)
AU (1) AU2006271308B2 (hu)
CA (2) CA2790675C (hu)
DK (2) DK1904093T3 (hu)
ES (2) ES2710601T3 (hu)
HR (1) HRP20181379T1 (hu)
HU (2) HUE040063T2 (hu)
NZ (2) NZ598031A (hu)
PL (2) PL1904093T3 (hu)
WO (1) WO2007010394A2 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598031A (en) 2005-07-19 2013-11-29 Stemgen S P A Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
WO2009101012A1 (en) * 2008-02-13 2009-08-20 Dkfz Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Methods for treating and preventing brain tumors based on bone morphogenetic proteins
US11578110B2 (en) 2015-08-25 2023-02-14 Histide Ag Compounds for inducing tissue formation and uses thereof
WO2017046226A2 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof.
CN109715190A (zh) * 2015-09-17 2019-05-03 伊斯迪德股份公司 将赘生性细胞转化成非赘生性细胞的生长因子受体激动剂和黏附蛋白抑制剂的药物缔合物及其用途
CN109715195A (zh) * 2015-09-17 2019-05-03 伊斯迪德股份公司 用于将赘生性细胞转化为非赘生性细胞的药物结合物及其用途
ES2900480T3 (es) * 2015-09-17 2022-03-17 Histide Ag Asociaciones farmacéuticas de agonistas de receptores de factor de crecimiento e inhibidores de proteínas de adhesión para la conversión de células neoplásicas en células no neoplásicas y usos de las mismas
EP3349777A2 (en) * 2015-09-17 2018-07-25 Histide AG Pharmaceutical association comprising a growth factor receptor agonist conjugated to a bioactive carrierfor converting a neoplastic cell into a non-neoplastic cell and uses thereof
EP3936149A4 (en) * 2018-12-28 2023-02-15 The University of Tokyo THERAPEUTIC AND PROPHYLACTIC AGENT FOR GLIOMA, BRAIN TUMOR MALIGNITY MARKER, BRAIN TUMOR PROGNOSTIC MARKER, METHOD FOR DETERMINING MALIGNITY AND PROGNOSTIC OF BRAIN TUMOR, AND ANTIBODIES INHIBITING TUMOR PROLIFERATION

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
DE69231726D1 (de) * 1991-12-24 2001-04-12 Amrad Corp Ltd Verwendung von leukämieinhibierendem faktor (lif) zur behandlung von tumoren und sarkomen
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US7592428B1 (en) * 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
DE69535641D1 (de) * 1994-04-29 2007-12-27 Curis Inc Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US6281015B1 (en) * 1994-12-16 2001-08-28 Children's Medical Center Corp. Localized delivery of factors enhancing survival of transplanted cells
US20010053371A1 (en) * 1999-01-07 2001-12-20 Waldemar Debinski Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6036920A (en) 1996-05-09 2000-03-14 3-Dimensional Pharmaceuticals, Inc. Microplate thermal shift assay apparatus for ligand development and multi-variable protein chemistry optimization
WO2000029012A2 (en) 1998-11-13 2000-05-25 Curis, Inc. Methods of alleviating cancer symptoms
AU784539B2 (en) * 1999-12-06 2006-04-27 Geistlich Pharma Ag Methods of treating tumors
CA2401989A1 (en) * 2000-03-03 2001-09-07 The Walter And Eliza Hall Institute Of Medical Research A method of treatment
WO2005026382A1 (en) 2003-09-12 2005-03-24 Stemcell Technologies Inc. Neural colony forming assay
JP2005098727A (ja) 2003-09-22 2005-04-14 Hosiden Corp 振動センサ
EP1697715A4 (en) 2003-12-05 2007-10-10 Univ Leland Stanford Junior IDENTIFICATION, INSULATION AND ELIMINATION OF CANCER STEM CELLS
JP4971149B2 (ja) * 2004-06-17 2012-07-11 スラソス セラピューティックス インコーポレーテッド Ｔｄｆ関連化合物およびその類似体
NZ598031A (en) * 2005-07-19 2013-11-29 Stemgen S P A Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
US10130590B2 (en) * 2013-10-01 2018-11-20 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds

Also Published As

Publication number Publication date
WO2007010394A2 (en) 2007-01-25
EP1904093A2 (en) 2008-04-02
WO2007010394A3 (en) 2007-08-30
KR101338533B1 (ko) 2013-12-12
PL1904093T3 (pl) 2018-12-31
DK3117833T3 (en) 2019-03-18
US20100167999A1 (en) 2010-07-01
AU2006271308A1 (en) 2007-01-25
US9220756B2 (en) 2015-12-29
NZ598031A (en) 2013-11-29
ES2710601T3 (es) 2019-04-26
EP3117833B1 (en) 2019-01-23
NZ565172A (en) 2012-12-21
HUE042197T2 (hu) 2019-06-28
EP1904093B1 (en) 2018-06-13
CA2615491A1 (en) 2007-01-25
JP2012107063A (ja) 2012-06-07
ES2686093T3 (es) 2018-10-16
PL3117833T3 (pl) 2019-06-28
JP5189977B2 (ja) 2013-04-24
JP2009502771A (ja) 2009-01-29
US9737589B2 (en) 2017-08-22
HRP20181379T1 (hr) 2018-11-16
CA2615491C (en) 2016-11-29
KR20120125990A (ko) 2012-11-19
CA2790675A1 (en) 2007-01-25
JP5891068B2 (ja) 2016-03-22
CA2790675C (en) 2016-12-20
KR101311061B1 (ko) 2013-09-25
KR20080082595A (ko) 2008-09-11
EP3117833A1 (en) 2017-01-18
DK1904093T3 (en) 2018-09-03
AU2006271308B2 (en) 2012-12-20
JP2015057452A (ja) 2015-03-26
US20160228511A1 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
HRP20181379T1 (hr) Inhibiranje tumorogenog potencijala tumorskih matičnih stanica s bmp-4
ZA200705783B (en) Amino-imidazolones for the inhibition of ß-secretase
HK1220208A1 (zh) 用於酶抑制的化合物
IL189933A0 (en) Rna antagonist compounds for the inhibition of apo-b100 expression
IL191832A0 (en) Pyridiazinone derivatives for the treatment of tumours
MX286273B (es) Composiciones y metodos para inhibicion de la via jak.
IL179020A0 (en) Compounds for enzyme inhibition
GB2424881B (en) Halophenyl derivatives of bisalkylfluorene
ZA200707639B (en) Methods of decreasing calcification
PT2056814E (pt) Compostos de 2,5-di-hidroxibenzeno para o tratamento da psoríase
HK1104235A1 (en) S-mirtazapine for the treatment of hot flush
WO2007014250A3 (en) Abl kinase inhibition
IL187449A0 (en) Variants at chr8q24.21 confer risk of cancer
GB0605685D0 (en) Inhibition of tumour growth
GB0803521D0 (en) A pharmaceutcal composition useful for the treatment of prostate cancer
EP1890761A4 (en) PROCESS FOR REINFORCING LIPOLYSIS
GB0517387D0 (en) Combinations for the treatment of cancer
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
GB2426765B (en) The preparation of multipotent stem cells
EP1931370A4 (en) USE OF DES-ASPARTATE-ANGIOTENSIN I
EP1873240A4 (en) GENE OF REGULATION OF THE EXPRESSION OF THE GENE hTERT
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
EP1905445A4 (en) HUMBLER OF TUMOR GROWTH
GB0517386D0 (en) Combinations for the treatment of cancer
GB0624636D0 (en) Self shutting doors-mechanical type area of the techniques